Low-dose metronomic chemotherapy: A systematic literature analysis

Lien, Kelly; Georgsdottir, Soley; Sivanathan, Lavarnan; Chan, Kelvin K.; Emmenegger, Urban

doi:10.1016/j.ejca.2013.06.038

Cited by 153 publications

(146 citation statements)

References 33 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…Therefore, it is inevitable and non-negligible that the PTX concentration will be far lower than the clinical dose in tumor tissues, especially in the later phase of one medication cycle. Clinically, restricted by the severe cytotoxic effects, the 'low-dose metronomic' chemotherapeutic pattern is preferable for most Asian patients [31] and the medication cycle of PTX usually contains long dosing intervals. These lead to the increased opportunity for exposure or prolonged exposure time to low-dose PTX in cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model

Liu

et al. 2016

The FEBS Journal

View full text Add to dashboard Cite

Paclitaxel is the most commonly used chemotherapeutic agent in breast cancer treatment. In addition to its well-known cytotoxic effects, recent studies have shown that paclitaxel has tumor-supportive activities. Importantly, paclitaxel levels are not maintained at the effective concentration through one treatment cycle; rather, the concentration decreases during the cycle as a result of drug metabolism. Therefore, a comprehensive understanding of paclitaxel's effects requires insight into the dose-specific activities of paclitaxel and their influence on cancer cells and the host microenvironment. Here we report that a low dose of paclitaxel enhances metastasis of breast cancer cells to the liver in mouse models. We used microarray analysis to investigate gene expression patterns in invasive breast cancer cells treated with low or clinically relevant high doses of paclitaxel. We also investigated the effects of low doses of paclitaxel on cell migration, invasion and metastasis in vitro and in vivo. The results showed that low doses of paclitaxel promoted inflammation and initiated the epithelial-mesenchymal transition, which enhanced tumor cell migration and invasion in vitro. These effects could be reversed by inhibiting NF-jB. Furthermore, low doses of paclitaxel promoted liver metastasis in mouse xenografts, which correlated with changes in estrogen metabolism in the host liver. Collectively, these findings reveal the paradoxical and dosedependent effects of paclitaxel on breast cancer cell activity, and suggest that increased consideration be given to potential adverse effects associated with low concentrations of paclitaxel during treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model

Liu

et al. 2016

The FEBS Journal

View full text Add to dashboard Cite

show abstract

“…33 In addition, various studies have confirmed the potential of metronomic chemotherapy to directly affect tumor cells themselves. 34 Accordingly, the cytotoxic effect imparted by metronomic S-1 dosing on both tumor endothelial cells of angiogenic vessels and tumor cells immediately adjacent to tumor vasculature ( Figure 2) is anticipated to enhance the tumor accumulation and broad distribution of PEGylated liposomes via not only increasing the intratumor space available for PEGylated liposome accumulation but also by alleviating the mechanical compression exerted on tumor blood vessels by proliferating tumor cells and, consequently, improve tumor perfusion ( Figure 3) and enhance the extravasation of PEGylated liposomes from tumor blood vessels resulting in deeper diffusion, broader distribution (Figure 4), and enhanced accumulation within the tumor tissue ( Figure 5A).…”

Section: Discussionmentioning

confidence: 99%

Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing

Doi

Lila

Matsumoto

et al. 2016

IJN

View full text Add to dashboard Cite

“…Metronomic chemotherapy is the regular administration of conventional chemotherapeutic drugs at low, minimally toxic doses, with no prolonged drug-free breaks [17][18][19] . This approach is attractive in clinical practice for patients with residual toxicity from earlier treatment and those whose age or frailty mean that they are not considered fit enough for conventional chemotherapy 20 .…”

Section: Discussionmentioning

confidence: 99%

Metronomic Chemotherapy with 5-Fluorouracil and Cisplatin for Inoperable Malignant Bowel Obstruction Because of Peritoneal Dissemination from Gastric Cancer

Yang

et al. 2016

Current Oncology

View full text Add to dashboard Cite

show abstract

Low-dose metronomic chemotherapy: A systematic literature analysis

Cited by 153 publications

References 33 publications

Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model

Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model

Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing

Metronomic Chemotherapy with 5-Fluorouracil and Cisplatin for Inoperable Malignant Bowel Obstruction Because of Peritoneal Dissemination from Gastric Cancer

Contact Info

Product

Resources

About